Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




SecA Inhibitors Block Growth of Methicillin-Resistant Staphylococcus aureus

By LabMedica International staff writers
Posted on 15 Dec 2015
A novel class of low molecular weight compounds has been shown to effectively inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious drug-resistant bacterial pathogens.

Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. More...
This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.

In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.

These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.

The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.

Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.

"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.

Related Links:

Georgia State University



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.